Featured Publication

Non-Targeted Metabolomics Provides New Insights into Parkinson’s Disease Research

Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by dopaminergic neuron loss, motor dysfunction, and progressive neurological decline. Increasing evidence suggests that neuroinflammation and abnormal astrocyte activation play important roles in the development and progression of PD. However, current therapeutic strategies mainly focus on symptom management and remain limited in their ability to slow or halt disease progression.

In a recent study published in Cellular and Molecular Life Sciences, researchers from Guangzhou Medical University and collaborating institutions investigated the therapeutic potential of RRx-001, a small-molecule immunomodulator, in an MPTP-induced Parkinson’s disease mouse model.

The study demonstrated that RRx-001 alleviates astrocyte pyroptosis by regulating the LCN2-NLRP3 inflammasome pathway, thereby reducing neuroinflammation and protecting dopaminergic neurons. In addition, the researchers explored the effects of RRx-001 on gut microbiota composition and metabolic profiles in the substantia nigra, providing a broader perspective on its role in PD-related pathological processes.

These findings highlight the LCN2-NLRP3 inflammasome-mediated astrocyte pyroptosis pathway as a potential therapeutic target for Parkinson’s disease and provide new insights into neuroinflammation-oriented intervention strategies.

BMKGENE supported this study by providing non-targeted metabolomics services, contributing to the metabolic profiling and mechanistic exploration of RRx-001 in Parkinson’s disease research.